Impact of p16 expression in oropharyngeal cancer in the postoperative setting : the necessity of re-evaluating traditional risk stratification

Abstract

Purpose: To evaluate the impact of p16 expression as a surrogate marker of human papillomavirus status in oropharyngeal squamous cell carcinoma (OPSCC) patients underwent surgery followed by postoperative radiotherapy (PORT). Patients and Methods: We identified 126 consecutive patients with histologically confirmed, newly diagnosed OPSCC who received surgery followed by RT, and had p16 expression data available. All patients were treated between 2001 and 2011. Patients with high risk factors (positive surgical margin and/or extracapsular extension) or other risk factors (multiple positive lymph nodes, perineural/lymphovascular invasion) were offered PORT with or without concurrent chemotherapy. Results: One hundred and four (82.5%) patients were p16-positive (p16 (+)) and 22 (17.5%) were p16-negative (p16 (-)). With a median follow-up of 56 months, patients with p16 (+) OPSCC exhibited a significantly better 5-year disease-free survival (DFS) (80.7% vs. 57.6%, p < 0.001) and overall survival (OS) (84.9% vs. 59.1%, p < 0.001) than those with p16 (-) tumors. The p16 (+) OPSCC with high risk factors (n=64) showed no difference in DFS (79.7% vs. 68.3%; p = 0.531) and OS (82.1% vs. 76.2%; p = 0.964) between PORT and PORT with concurrent chemotherapy. Conclusion: Expression of p16 is a strong, independent prognostic factor of survival in the postoperative setting of OPSCC. The favorable prognosis of p16 (+) OPSCC suggests a need to re-examine traditional risk stratification for determining optimal adjuvant treatment.